A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma
Latest Information Update: 07 Sep 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 26 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Nov 2012 Planned End Date changed from 1 Nov 2007 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 08 Mar 2012 Planned end date (Nov 2007) added as reported by ClinicalTrials.gov.